Welcome to our dedicated page for Quotient news (Ticker: QTNT), a resource for investors and traders seeking the latest updates and insights on Quotient stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quotient's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quotient's position in the market.
Quotient Limited (NASDAQ: QTNT) announced the appointment of Thomas Aebischer to its Board of Directors, effective May 1, 2022. Aebischer will also join the Audit Committee. He brings over 30 years of financial expertise, previously serving as CFO at RWDC Ltd., LyondellBasell Industries, and Holcim Group. Quotient, based in Switzerland, the US, and Scotland, specializes in revolutionary diagnostic solutions through its MosaiQ technology, which aims to enhance laboratory efficiencies and reduce operational costs.
Quotient Limited (NASDAQ: QTNT) has announced that the New York Blood Center, Inc. and Centro de Transfusiones de la Comunidad de Madrid have joined the MosaiQ Innovator’s Circle to enhance patient care and laboratory efficiencies. This initiative currently involves six laboratories from the US and Europe, with more collaborations underway. Quotient is also launching an Investigator Initiated Research program to assess the clinical and economic benefits of the MosaiQ system, which aims to transform transfusion diagnostics through its automated and consolidated testing platform.
Quotient Limited (NASDAQ:QTNT) has received the CE Mark for its MosaiQ Extended Immunohematology Microarray, allowing commercialization across the EU. This platform simplifies blood testing with improved workflow, reduced operating costs, and a broader range of tests, including Antibody Screening and Antigen Typing. CE marking confirms compliance with European Medical Devices Directive. The CEO highlighted the potential for better matched blood transfusions, reducing life-threatening risks. Quotient aims to enhance diagnostics based on over 30 years of experience in transfusion diagnostics.
Quotient Limited (NASDAQ:QTNT) announced its participation in the Cowen 42nd Annual Health Care Conference, with a fireside chat scheduled for March 9, 2022, at 11:00 am ET. The company focuses on transfusion diagnostics and offers MosaiQ, an innovative multiplex microarray technology. This platform allows for fully automated testing across various modalities, aiming to enhance laboratory efficiency, clinical practice, and cost savings globally. Quotient operates from locations in Switzerland, Scotland, and Pennsylvania.
Quotient reported a 16% year-over-year revenue growth, totaling $10.2 million in Q3 2022, driven by increased OEM sales. The company anticipates raising its FY Alba sales outlook to between $36 million and $37 million. Quotient is preparing for potential CE marking approval for its MosaiQ Expanded Immunohematology microarray within the EU. However, the company faces challenges with rising operating expenses and an accumulated deficit of $699.1 million, which raises doubts about its ability to continue as a going concern.
Quotient Limited (NASDAQ:QTNT) announced its participation in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. The management team will conduct a fireside chat on February 17, 2022, at 8:00 AM ET. This conference is exclusive to BTIG clients, and those interested in a one-on-one meeting or listening to the live event should contact their BTIG representative. Quotient, with over 30 years in transfusion diagnostics, is committed to reshaping diagnostic practices with its innovative MosaiQ platform, which enhances efficiency and reduces costs for laboratories globally.
On February 1, 2022, Quotient Limited (NASDAQ:QTNT) appointed Esteban Uriarte as Chief Manufacturing Operations Officer. To incentivize his joining, the Company granted him 173,994 performance-based restricted share units (PSUs), 104,396 restricted share units (RSUs), and options to purchase 106,983 ordinary shares. These grants are not part of the 2014 Stock Incentive Plan and were approved as per Nasdaq Rule 563(c)(4). The PSUs will vest based on financial performance, while the RSUs and options will vest in three installments over three years, contingent upon Uriarte's continued service.
Quotient Limited (NASDAQ:QTNT) announced its first-time attendance at the Arab Health and Medlab Middle East 2022 conference in Dubai, aiming to enhance its global presence. The company held fruitful discussions with potential distributors from the Middle East, Europe, and Asia-Pacific, indicating growing interest in its MosaiQ solution. Quotient anticipates receiving Expanded IH CE mark approval by the end of Q1 CY22, crucial for its product development. The MosaiQ platform promises significant efficiencies and cost savings in laboratory diagnostics, leveraging over 30 years of experience in transfusion diagnostics.
Quotient Limited (NASDAQ: QTNT) will release its fiscal third-quarter financial results for the period ending December 31, 2021, on February 8, 2022. A conference call to discuss these results will take place at 8:00 am Eastern Time, with dial-in numbers provided for US and international participants. Quotient aims to reshape diagnostics with its MosaiQ technology, a fully automated testing platform intended to enhance efficiency and reduce operational costs in laboratories globally. The replay of the conference call will be available until February 15, 2022.
Quotient Limited (NASDAQ:QTNT) held a Scientific Advisory Board meeting featuring eight Key Opinion Leaders from the US and Europe. The focus was on enhancing the scientific and medical validation of the MosaiQ system through new programs including the Innovator’s Circle and Investigator Initiated Research. These initiatives aim to demonstrate operational and workflow benefits within laboratories. Quotient's management, including Dr. Christine Ginocchio and CEO Manuel O. Méndez, highlighted the importance of collaboration to improve laboratory efficiency and patient outcomes.
